Bb2121: New CAR T-Cell Therapy for Multiple Myeloma

A phase 1 clinical trial reports that bb2121, a chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA), has shown antitumor activity in relapsed/refractory multiple myeloma. A form of immunotherapy, CAR T-cell therapy involves adding a CAR to the patient's cytotoxic T cells, transforming the T cells into CAR T cells. After this modification, which is done in the laboratory, the CAR T cells are reinjected into the patient's bloodstream, where they multiply and a...

Continue reading

Multiple Myeloma: bb2121 CAR T-Cell Therapy With James Kochenderfer, MD

Chimeric antigen receptor (CAR) T-cell therapy has shown great promise in hematologic malignancies, with treatments currently FDA approved for aggressive, refractory non-Hodgkin lymphoma and for relapsed/refractory acute lymphoblastic leukemia in patients up to the age of 25. Now, a phase 1 clinical trial of bb2121, a CAR T-cell therapy targeting B-cell maturation antigen (BCMA), has demonstrated antitumor activity in patients with heavily pretreated multiple myeloma. In this interview with i3 H...

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.